stockrow
Friday 6 November 2026
Export IRON’s income statement to Excel — free account
Disc Medicine, Inc.
IRON Healthcare Biotechnology
- EPS
- +2.53%
- Free cash flow
- +7.83%
- Total debt
- +106.5%
Quarter to June 2026, against a year earlier
78.51
0.04
+0.05%
Follow IRON
Alert me
Disc Medicine, Inc. (IRON) Gross margin
Disc Medicine, Inc.'s gross margin over the twelve months to 30 September 2023 was 0.00%, down 0.0 percentage points from fiscal 2022 (0.00%). That is below the Biotechnology industry median of 65.2% and below the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2023 | 0.00% | 0.00 |
| Jun 2023 | 0.00% | 0.00 |
| Mar 2023 | 0.00% | 0.00 |
| Dec 2022 | 0.00% | 0.00 |
| 4 more quarters | Free account |
Gross margin against peers
| Company | Gross margin |
|---|---|
| RLAY Relay Therapeutics, Inc. compare | 100.0% |
| TNGX Tango Therapeutics, Inc. compare | 100.0% |
| ACAD ACADIA Pharmaceuticals Inc. compare | 90.5% |
| XENE Xenon Pharmaceuticals Inc. compare | 28.4% |
| DYN Dyne Therapeutics, Inc. compare | 0.00% |
| IOVA Iovance Biotherapeutics, Inc. compare | 0.00% |
| IRON Disc Medicine, Inc. | 0.00% |
| VKTX Viking Therapeutics, Inc. compare | 0.00% |
| PBLS Parabilis Medicines, Inc. compare | — |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue